Anti-factor Xa (Anti-Xa) assay

Methods in Molecular Biology

Volumn 992, Issue , 2013, Pages 265-272

  Newall, Fiona ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anti Xa assay; Chromogenic test; Heparin monitoring; LMWH monitoring

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10A ANTIBODY; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG;

ANTI FACTOR XA ASSAY; ARTICLE; ASSAY; PRIORITY JOURNAL; STANDARDIZATION;

EID: 84877124284     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-339-8_19     Document Type: Article

References (23)

1. Olson J, Arkin C, Brandt J, Cunningham M, Giles A, Koepke J, Witte D (1998) College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122:782-798
2. Laffan M, Manning R (2001) Laboratory control of anticoagulant, thrombolytic and antiplatelet therapy (Chapter 18). In: Lewis S, Bain B, Bates I (eds) Dacie and Lewis: Practical haematology, 9th edn. Churchill Livingstone, London, pp 465-479
3. Levine M, Hirsh J, Gent M, Turpie A, Cruisckshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49-56
4. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin. Chest 126: 188S-203S
5. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, DeRosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Rowlands S (2006) Developmental haemostasis: Impact for clinical haemostasis laboratories. Thromb Haemost 95:362-372
6. Kovacs M, Keeney M, MacKinnon K, Boyle E (1999) Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 21:55-60
7. Kitchen S, Theaker J, Preston F (2000) Monitoring unfractionated heparin therapy: Relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 11:137-144
8. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennet M, Shann F, Lane G, Ross-Smith M, Monagle P (2007) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thromb Res 120:347-351
9. Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P (2006) Therapeutic range for unfractionated heparin therapy: Age-related differences in response in children. J Thromb Haemost 4:2280-2282
10. Kitchen S (2000) Problems in laboratory monitoring of heparin dosage. Br J Haematol 111:397-406
11. Walenga J, Fareed J, Hoppensteadt D (1985) In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight heparin. Semin Thromb Hemost 11:17-25
12. Barrowcliffe T, Mulloy B, Johnson E, Thomas D (1989) The anticoagulant activity of heparin: Measurement and relationship to chemical structure. J Pharm Biomed Anal 7:217-226
13. Triplett D (1979) Heparin: Biochemistry, therapy, and laboratory monitoring. Ther Drug Monit 1:173-197
14. Nelson D (1999) Current considerations in the use of the APTT in monitoring unfractionated heparin. Clin Lab Sci 12:359-364
15. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson A (2004) Antithrombotic therapy in children. Chest 126:645S-687S
16. Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, Cheng K, Monagle P (2006) Age-related differences in heparin response. Thromb Res 118:741-745
17. Chan A, Black L, Ing C, Brandao L, Williams S (2007) Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res 122:135-136
18. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A, Mitchell L (2007) Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 92:554-557
19. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P (2010) Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 103:1085-1090
20. Standards N (ed) (1998) Collection, transport and processing of blood specimens for coagulation testing and general performance of coagulation assays. NCCLS, Wayne, PA
21. Reneke J, Etzell J, Leslie S (1998) Prolonged prothrombin time and activated partial thromboplastin time due to under fi lled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol 109:754-757
22. Rose VL, Dermott SC, Murray BF, McIver MM, High KA (1993) Decentralized testing for PT and activated PTT using a dry chemistry portable analyzer. Arch Pathol Lab Med 117:611-617
23. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennet M, Shann F, Lane G, Ross-Smith M, Monagle P (2006) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? J Thromb Haemost 120:347-351